This is not the most recent version of the article. View current version (23 MAY 2014)

Intervention Protocol

Ipratropium bromide for stable chronic obstructive pulmonary disease

  1. Richard Wood-Baker2,
  2. Ramy Khalil1,*,
  3. Myriam Girgis3

Editorial Group: Cochrane Airways Group

Published Online: 15 JUN 2011

DOI: 10.1002/14651858.CD001391.pub4


How to Cite

Wood-Baker R, Khalil R, Girgis M. Ipratropium bromide for stable chronic obstructive pulmonary disease (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 6. Art. No.: CD001391. DOI: 10.1002/14651858.CD001391.pub4.

Author Information

  1. 1

    University of Tasmania, Launceston School of Medicine, Tasmania, Australia

  2. 2

    University of Tasmania, Menzies Research Institute, Hobart, Tasmania, Australia

  3. 3

    University of Tasmania, Launceston General Hospital, Tasmania, Australia

*Ramy Khalil, Launceston School of Medicine, University of Tasmania, Tasmania, Australia. ramykhalill@gmail.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 15 JUN 2011

SEARCH

This is not the most recent version of the article. View current version (23 MAY 2014)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

  1. To assess in adults with COPD whether the regular use of ipratropium bromide compared to placebo is more effective in improving lung function and reducing symptoms
  2. To assess the adverse effect profile of ipratropium bromide compared to placebo.